Innovent Biologics (HK:1801) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Innovent Biologics has announced the inclusion of its drug Sintbilo (tafolecimab injection) and a new indication for Olverembatinib in China’s National Reimbursement Drug List for 2024, effective January 2025. This marks Innovent’s entry into the cardiovascular and metabolic field in China, potentially increasing the accessibility and affordability of these treatments for patients. Investors may find this development promising as it positions Innovent for growth in the Chinese pharmaceutical market.
For further insights into HK:1801 stock, check out TipRanks’ Stock Analysis page.